FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885745969> ?p ?o ?g. }

• W2885745969 abstract "TAK-659 is a highly potent, reversible inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3) that is currently being investigated in Phase I and II clinical trials. SYK is expressed ubiquitously in hematopoietic cells, and abnormal function of SYK has been implicated in several types of hematopoietic malignancies, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and peripheral T-cell lymphoma (PTCL). Although there are considerable data supporting a role for SYK signaling in hematological cancers, data on the relevance of SYK in solid tumors are emerging. The literature suggests that SYK expression plays a role in the growth of breast and ovarian cancers, and the pancreatic adenocarcinoma microenvironment has been shown to be B-cell rich, giving us a basis to explore the activity of TAK-659 in these indications. Furthermore, ovarian cancer patients with recurrent disease have been shown to have an increase in pSYK at the time of relapse versus at diagnosis, suggesting a role for SYK in chemoresistance. The ability of TAK-659 to inhibit ex vivo colony formation of cells with the ability to grow anchorage independently in semi-solid medium was examined in 31 different human tumor xenografts. TAK-659 showed concentration-dependent inhibition of tumor colony growth in 5/31 tumor models tested, including gastric, breast, and ovarian cancers. Pre-clinically, TAK-659 has exhibited significant antitumor activity in a number of mouse xenograft models of solid tumors. We demonstrate here that daily oral administration of TAK-659 at 60mg/kg over 21 days leads to significant antitumor activity in primary human tumor models of gastric, pancreatic, triple negative breast (TNBC), and ovarian cancers, all of which express pSYK. Significant anti-tumor activity was also observed in the HCC70 TNBC xenograft model which does not express total SYK, demonstrating that TAK-659 may have anti-tumor effects beyond the inhibition of pSYK signaling. A decrease in myeloid derived suppressor cells was seen following TAK-659 treatment in this xenograft model, suggesting an immunomodulatory response may be driving the antitumor activity. Taken together, these data along with published information support the rationale for the investigation of TAK-659 in solid tumor cancer indications. Citation Format: Jessica J. Sappal, Matthew Theisen, Zhongmin Xiang, Stephen Tirrell, Rudy Christmas, Jie Yu, Mengkun Zhang, Karuppiah Kannan. TAK-659, a SYK kinase inhibitor, demonstrates preclinical antitumor activity in solid tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3844." @default.
• W2885745969 created "2018-08-22" @default.
• W2885745969 creator A5008808358 @default.
• W2885745969 creator A5021037922 @default.
• W2885745969 creator A5030715835 @default.
• W2885745969 creator A5035815873 @default.
• W2885745969 creator A5075255310 @default.
• W2885745969 creator A5085125820 @default.
• W2885745969 creator A5089628127 @default.
• W2885745969 creator A5090472849 @default.
• W2885745969 date "2018-07-01" @default.
• W2885745969 modified "2023-09-25" @default.
• W2885745969 title "Abstract 3844: TAK-659, a SYK kinase inhibitor, demonstrates preclinical antitumor activity in solid tumor models" @default.
• W2885745969 doi "https://doi.org/10.1158/1538-7445.am2018-3844" @default.
• W2885745969 hasPublicationYear "2018" @default.
• W2885745969 type Work @default.
• W2885745969 sameAs 2885745969 @default.
• W2885745969 citedByCount "0" @default.
• W2885745969 crossrefType "proceedings-article" @default.
• W2885745969 hasAuthorship W2885745969A5008808358 @default.
• W2885745969 hasAuthorship W2885745969A5021037922 @default.
• W2885745969 hasAuthorship W2885745969A5030715835 @default.
• W2885745969 hasAuthorship W2885745969A5035815873 @default.
• W2885745969 hasAuthorship W2885745969A5075255310 @default.
• W2885745969 hasAuthorship W2885745969A5085125820 @default.
• W2885745969 hasAuthorship W2885745969A5089628127 @default.
• W2885745969 hasAuthorship W2885745969A5090472849 @default.
• W2885745969 hasConcept C109159458 @default.
• W2885745969 hasConcept C121608353 @default.
• W2885745969 hasConcept C126322002 @default.
• W2885745969 hasConcept C170493617 @default.
• W2885745969 hasConcept C2776107976 @default.
• W2885745969 hasConcept C2777938653 @default.
• W2885745969 hasConcept C2778461978 @default.
• W2885745969 hasConcept C28328180 @default.
• W2885745969 hasConcept C35174551 @default.
• W2885745969 hasConcept C42362537 @default.
• W2885745969 hasConcept C502942594 @default.
• W2885745969 hasConcept C54355233 @default.
• W2885745969 hasConcept C71924100 @default.
• W2885745969 hasConcept C86803240 @default.
• W2885745969 hasConceptScore W2885745969C109159458 @default.
• W2885745969 hasConceptScore W2885745969C121608353 @default.
• W2885745969 hasConceptScore W2885745969C126322002 @default.
• W2885745969 hasConceptScore W2885745969C170493617 @default.
• W2885745969 hasConceptScore W2885745969C2776107976 @default.
• W2885745969 hasConceptScore W2885745969C2777938653 @default.
• W2885745969 hasConceptScore W2885745969C2778461978 @default.
• W2885745969 hasConceptScore W2885745969C28328180 @default.
• W2885745969 hasConceptScore W2885745969C35174551 @default.
• W2885745969 hasConceptScore W2885745969C42362537 @default.
• W2885745969 hasConceptScore W2885745969C502942594 @default.
• W2885745969 hasConceptScore W2885745969C54355233 @default.
• W2885745969 hasConceptScore W2885745969C71924100 @default.
• W2885745969 hasConceptScore W2885745969C86803240 @default.
• W2885745969 hasLocation W28857459691 @default.
• W2885745969 hasOpenAccess W2885745969 @default.
• W2885745969 hasPrimaryLocation W28857459691 @default.
• W2885745969 hasRelatedWork W2040604274 @default.
• W2885745969 hasRelatedWork W2066858437 @default.
• W2885745969 hasRelatedWork W2100751415 @default.
• W2885745969 hasRelatedWork W2124138175 @default.
• W2885745969 hasRelatedWork W2140116346 @default.
• W2885745969 hasRelatedWork W2326230237 @default.
• W2885745969 hasRelatedWork W2577781255 @default.
• W2885745969 hasRelatedWork W2593938549 @default.
• W2885745969 hasRelatedWork W2885745969 @default.
• W2885745969 hasRelatedWork W2914867163 @default.
• W2885745969 isParatext "false" @default.
• W2885745969 isRetracted "false" @default.
• W2885745969 magId "2885745969" @default.
• W2885745969 workType "article" @default.